Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients

Jan Remsik, Jessica A. Wilcox, N. Esther Babady, Tracy A. McMillen, Behroze A. Vachha, Neil A. Halpern, Vikram Dhawan, Marc Rosenblum, Christine A. Iacobuzio-Donahue, Edward K. Avila, Bianca Santomasso, Adrienne Boire

Research output: Contribution to journalArticlepeer-review

30 Scopus citations

Abstract

Remsik et al. analyze the cerebrospinal fluid of cancer patients with neurologic symptoms of COVID-19 and detect unique markers of inflammation and neurodegeneration, present weeks after initial SARS-CoV-2 infection. Cytokine storming, both systemically and intracranially, likely contribute to neurologic dysfunction, indicating a potential therapeutic target for investigation.

Original languageEnglish
Pages (from-to)276-283.e3
JournalCancer Cell
Volume39
Issue number2
DOIs
StatePublished - 8 Feb 2021
Externally publishedYes

Keywords

  • COVID-19
  • SARS-CoV-2
  • cancer
  • cerebrospinal fluid
  • encephalopathy
  • neuroinflammation

Fingerprint

Dive into the research topics of 'Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients'. Together they form a unique fingerprint.

Cite this